{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:48:53Z","timestamp":1779306533357,"version":"3.51.4"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/wco.0000000000000099","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T15:59:53Z","timestamp":1397663993000},"page":"260-270","source":"Crossref","is-referenced-by-count":63,"title":["Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI"],"prefix":"10.1097","volume":"27","author":[{"given":"Mike P.","family":"Wattjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210206","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease.","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R2-4-20210206","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"R3-4-20210206","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1212\/WNL.61.6.734","article-title":"The uninvited guest. JC virus infection of neurons in PML.","volume":"61","author":"Tyler","year":"2003","journal-title":"Neurology"},{"key":"R4-4-20210206","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(09)70226-9","article-title":"Progressive multifocal leukoencephalopathy in HIV-1 infection.","volume":"9","author":"Cinque","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12206","article-title":"Requirement for safety monitoring for approved MS therapies: an overview.","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R6-4-20210206","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond.","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol"},{"key":"R7-4-20210206","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"R8-4-20210206","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"R9-4-20210206","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.","volume":"18","author":"Sorensen","year":"2012","journal-title":"Mult Scler"},{"key":"R10-4-20210206","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","article-title":"Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.","volume":"78","author":"Blair","year":"2012","journal-title":"Neurology"},{"key":"R11-4-20210206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2013.00011","article-title":"Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"4","author":"Linda","year":"2013","journal-title":"Front Neurol"},{"key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/1352458513481010","article-title":"Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.","volume":"19","author":"Blinkenberg","year":"2013","journal-title":"Mult Scler"},{"key":"R13-4-20210206","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00415-012-6426-5","article-title":"Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.","volume":"259","author":"Ayzenberg","year":"2012","journal-title":"J Neurol"},{"key":"R14-4-20210206","first-page":"415873","article-title":"Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.","volume":"2013","author":"Manenti","year":"2013","journal-title":"Case Rep Radiol"},{"key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab.","volume":"260","author":"Mc Govern","year":"2013","journal-title":"J Neurol"},{"key":"R16-4-20210206","first-page":"1067","article-title":"The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas N","volume":"79","author":"Phan-Ba","year":"2012","journal-title":"eurology"},{"key":"R17-4-20210206","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R18-4-20210206","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"issue":"Suppl 4","key":"R19-4-20210206","first-page":"2799","article-title":"Imaging findings for PML in natalizumab-treated MS patients.","volume":"18","author":"Richert","year":"2012","journal-title":"Mult Scler"},{"key":"R20-4-20210206","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section.","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2012-302478","article-title":"Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies.","volume":"83","author":"Mentzer","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","article-title":"Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.","volume":"77","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00234-003-1115-9","article-title":"Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations.","volume":"46","author":"Bergui","year":"2004","journal-title":"Neuroradiology"},{"key":"R25-4-20210206","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-4-20210206","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1440-1789.2008.00981.x","article-title":"Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia.","volume":"29","author":"Takeda","year":"2009","journal-title":"Neuropathology"},{"key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/13550280701469178","article-title":"Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.","volume":"13","author":"Bernal-Cano","year":"2007","journal-title":"J Neurovirol"},{"key":"R28-4-20210206","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1212\/01.wnl.0000439052.05262.1d","article-title":"Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.","volume":"81","author":"Bourre","year":"2013","journal-title":"Neurology"},{"key":"R29-4-20210206","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1212\/WNL.0b013e3182918d27","article-title":"Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.","volume":"80","author":"Yeung","year":"2013","journal-title":"Neurology"},{"key":"R30-4-20210206","first-page":"1131","article-title":"Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis.","volume":"6","author":"Herold","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R31-4-20210206","first-page":"162","article-title":"Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name Ann N","volume":"60","author":"Koralnik","year":"2006","journal-title":"eurol"},{"key":"R32-4-20210206","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","article-title":"Progressive multifocal leukoencephalopathy: why grey and white matter.","volume":"8","author":"Gheuens","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"R33-4-20210206","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/01.wnl.0000284601.54436.e4","article-title":"Cortical demyelination in PML and MS: similarities and differences.","volume":"70","author":"Moll","year":"2008","journal-title":"Neurology"},{"key":"R34-4-20210206","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.","volume":"71","author":"Kleinschmidt-DeMasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"R35-4-20210206","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"R36-4-20210206","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy.","volume":"361","author":"Linda","year":"2009","journal-title":"N Engl J Med"},{"issue":"S1","key":"R37-4-20210206","first-page":"879","article-title":"Survival and functional outcome in asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy multiple sclerosis patients abstract.","volume":"19","author":"Dong-Si","year":"2013","journal-title":"Mult Scler"},{"key":"R39-4-20210206","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"R40-4-20210206","first-page":"1176","article-title":"Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation J Neurol Neurosurg P","volume":"84","author":"Wattjes","year":"2013","journal-title":"sychiatry"},{"key":"R41-4-20210206","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","article-title":"Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management.","volume":"79","author":"Antoniol","year":"2012","journal-title":"Neurology"},{"key":"R42-4-20210206","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/01.wnl.0000343735.44983.5e","article-title":"Steroids for PML-IRIS. A double-edged sword.","volume":"72","author":"Berger","year":"2009","journal-title":"Neurology"},{"key":"R43-4-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R44-4-20210206","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/NEN.0000000000000005","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.","volume":"72","author":"Wuthrich","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"R45-4-20210206","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e31820b7644","article-title":"Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.","volume":"76","author":"Vennegoor","year":"2011","journal-title":"Neurology"},{"key":"R46-4-20210206","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneurol.2009.57","article-title":"Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.","volume":"66","author":"Seewann","year":"2009","journal-title":"Arch Neurol"},{"key":"R47-4-20210206","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.","volume":"361","author":"Wenning","year":"2009","journal-title":"N Engl J Med"},{"key":"R48-4-20210206","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/jamaneurol.2013.1960","article-title":"Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.","volume":"70","author":"Boster","year":"2013","journal-title":"JAMA Neurol"},{"key":"R49-4-20210206","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML.","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"R50-4-20210206","first-page":"831","article-title":"Immune reconstitution inflammatory syndrome after withdrawal of natalizumab N","volume":"75","author":"Lenhard","year":"2010","journal-title":"eurology"},{"key":"R51-4-20210206","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/01.WNL.0000081306.86961.33","article-title":"Productive infection of cerebellar granule cell neurons by JC virus in an HIV individual.","volume":"61","author":"Du Pasquier","year":"2003","journal-title":"Neurology"},{"key":"R52-4-20210206","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy.","volume":"57","author":"Koralnik","year":"2005","journal-title":"Ann Neurol"},{"key":"R53-4-20210206","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.21619","article-title":"Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons.","volume":"65","author":"Wutrich","year":"2009","journal-title":"Ann Neurol"},{"key":"R54-4-20210206","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.23973","article-title":"JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.","volume":"74","author":"Schippling","year":"2013","journal-title":"Ann Neurol"},{"key":"R55-4-20210206","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"R56-4-20210206","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.","volume":"84","author":"Dahlhaus","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R58-4-20210206","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"R59-4-20210206","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/1352458511431073","article-title":"Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.","volume":"18","author":"Rispens","year":"2012","journal-title":"Mult Scler"},{"key":"R60-4-20210206","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation.","volume":"75","author":"Fine","year":"2014","journal-title":"Ann Neurol"},{"key":"R61-4-20210206","first-page":"462","article-title":"PML after natalizumab discontinuation: few and true Ann N","volume":"75","author":"Wattjes","year":"2014","journal-title":"eurol"},{"key":"R62-4-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archneurol.2009.31","article-title":"Progresive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.","volume":"66","author":"Boster","year":"2009","journal-title":"Arch Neurol"},{"key":"R63-4-20210206","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00234-009-0512-0","article-title":"High field MRI in the diagnosis of multiple sclerosis: high field-high yield N","volume":"51","author":"Wattjes","year":"2009","journal-title":"euroradiology"},{"key":"R64-4-20210206","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nic.2012.02.010","article-title":"Inflammation high-field magnetic resonance imaging.","volume":"22","author":"Kilsdonk","year":"2012","journal-title":"Neuroimaging Clin N Am"},{"key":"R65-4-20210206","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00330-013-3080-y","article-title":"Improved differentiation between MS and vascular brain lesions using FLAIR at 7 Tesla.","volume":"24","author":"Kilsdonk","year":"2014","journal-title":"Eur Radiol"},{"key":"R66-4-20210206","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1212\/WNL.0b013e3182735cb3","article-title":"Tumefactive multiple sclerosis lesions under fingolimod treatment.","volume":"79","author":"Visser","year":"2012","journal-title":"Neurology"},{"key":"R67-4-20210206","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.","volume":"18","author":"Jander","year":"2012","journal-title":"Mult Scler"},{"key":"R68-4-20210206","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","article-title":"Tumefactive MS lesions under fingolimod: a case report and literature review.","volume":"81","author":"Pilz","year":"2013","journal-title":"Neurology"},{"key":"R69-4-20210206","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1352458512448268","article-title":"Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.","volume":"19","author":"Decard","year":"2013","journal-title":"Mult Scler"},{"key":"R70-4-20210206","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1352458513501572","article-title":"Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.","volume":"20","author":"Hradilek","year":"2014","journal-title":"Mult Scler"},{"key":"R71-4-20210206","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.","volume":"57","author":"Fine","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R72-4-20210206","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy.","volume":"368","author":"van Oosten","year":"2013","journal-title":"N Engl J Med"},{"key":"R73-4-20210206","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11910-013-0408-6","article-title":"Progressive multifocal leukoencephalopathy in multiple sclerosis.","volume":"13","author":"Chalkley","year":"2013","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0000000000000099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:53:52Z","timestamp":1620978832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201406000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0000000000000099","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}